Desvenlafaxine Tablet, Extended Release
Product Images NDC 70436-013

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 70436-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-1000ct (100mg 1000ct)

Desvenlafaxine Extended-Release Tablets 100 mg label from Slate Run Pharmaceuticals, LLC. The label includes storage instructions, manufacturing and distribution details, and a note for pharmacists to dispense a medication guide. The bottle contains 1,000 extended-release tablets.*

FDA Label Image

100mg-30ct (100mg 30ct)

Label for Desvenlafaxine Extended-Release Tablets, 100 mg, by Slate Run Pharmaceuticals, LLC. The label includes dosage form as extended-release tablets, quantity of 30 tablets, and storage instructions. It states the active ingredient as 152 mg desvenlafaxine succinate equivalent to 100 mg desvenlafaxine. Manufactured by Yichang Humanwell Oral Solid Dosage Plant in China, distributed by Slate Run Pharmaceuticals in Ohio.*

FDA Label Image

100mg-90ct (100mg 90ct)

Label for Desvenlafaxine Extended-Release Tablets 100 mg, oral tablets provided by Slate Run Pharmaceuticals, LLC. The label includes the NDC number 70436-013-06, storage instructions, and manufacturer information (Yichang Humanwell Oral Solid Dosage Plant, China). The package contains 90 tablets.*

FDA Label Image

25mg 30ct

Label for Desvenlafaxine Extended-Release Tablets 25 mg by Slate Run Pharmaceuticals, LLC. The label includes dosage information stating each tablet contains 38 mg desvenlafaxine succinate equivalent to 25 mg desvenlafaxine, storage instructions, manufacturer and distributor details, and a barcode. The package contains 30 tablets and advises pharmacists to dispense the medication guide to patients.*

FDA Label Image

50mg-30ct (50mg 30ct)

Desvenlafaxine Extended-Release Tablets label for the 50 mg strength, presented in a package of 30 tablets. The label includes storage instructions and manufacturer information, showing Slate Run Pharmaceuticals, LLC as the distributor and Yichang Humanwell Oral Solid Dosage Plant in China as the manufacturer. The label also instructs pharmacists to dispense the accompanying Medication Guide to patients.*

FDA Label Image

50mg-90ct (50mg 90ct)

Label for Desvenlafaxine Extended-Release Tablets 50 mg by Slate Run Pharmaceuticals, LLC. The label shows a package size of 90 tablets and includes storage instructions, manufacturer information (Yichang Humanwell Oral Solid Dosage Plant, China), and a barcode. It notes each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine.*

FDA Label Image

Des-structure (Des Structure)

Chemical structure diagram depicting the molecular formula of Desvenlafaxine, including its core aromatic ring and associated functional groups as shown in the image.*

FDA Label Image

Figure-1 (Figure 1)

A forest plot chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for Desvenlafaxine across different levels of renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population subgroups based on gender and age (females, 65-75 years, >75 years). The x-axis represents the change relative to reference, ranging from 0.5 to 3.5.*

FDA Label Image

Figure-2 (Figure 2)

A horizontal bar chart showing the geometric mean ratio (90% CI) for pharmacokinetic parameters Cmax and AUC of Desvenlafaxine when influenced by the CYP3A4 inhibitor Ketoconazole. The chart compares changes relative to a reference, with values approximately 1.08 for Cmax and 1.43 for AUC, each with confidence intervals displayed.*

FDA Label Image

Figure-3 (Figure 3)

A forest plot chart showing geometric mean ratios (90% confidence intervals) of pharmacokinetic (PK) changes caused by Desvenlafaxine at various dosages (50 mg, 100 mg, 400 mg) on interacting drugs that are CYP2D6, CYP3A4, or both substrate types. Drugs represented include Desipramine, Midazolam, Tamoxifen, and Aripiprazole, with Cmax and AUC (area under the curve) or related PK parameters compared relative to reference values.*

FDA Label Image

Figure-4 (Figure 4)

A line graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. Two groups are represented: Desvenlafaxine Extended-Release Tablets 50 mg (solid blue line) and Placebo (dashed red line). The graph compares relapse rates up to approximately 190 days.*

FDA Label Image

Figure-5 (Figure 5)

A Kaplan-Meier curve graph comparing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph shows two lines: a solid blue line representing Desvenlafaxine Extended-Release Tablets and a dashed red line representing placebo. The y-axis ranges from 0 to 50 percent, and the x-axis ranges from 0 to 200 days, illustrating lower relapse rates over time for the Desvenlafaxine group compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.